Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending February 18, 2011. The report details a specific share repurchase transaction executed under shareholder authority granted at the Annual General Meeting on May 6, 2010.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on capital structure changes related to share buybacks.
- Shares Purchased: 417,000 Ordinary shares of 25 pence each.
- Price Range: Highest price paid was 1,198.0 pence per share; lowest price paid was 1,175.0 pence per share.
- Treasury Holdings (Settled): 481,887,284 shares (8.50% of total issued share capital).
- Treasury Holdings (Including Unsettled): 483,179,284 shares (9.31% of total voting rights).
- Shares in Issue (Excluding Treasury): 5,188,911,465 shares.
Material Changes
The primary material change reported is the reduction of outstanding shares through the purchase of 417,000 shares on February 18, 2011. This transaction increased the proportion of shares held in Treasury to 9.31% of total voting rights when including unsettled purchases.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on operational outlook, or discussion of risks and contingencies. The document is a routine disclosure of a share repurchase event.
Investor Verification Checklist
- Verify the total number of shares held in Treasury (481,887,284 settled vs. 483,179,284 including unsettled).
- Confirm the percentage of total voting rights represented by Treasury shares (9.31%).
- Check the number of shares in issue excluding Treasury (5,188,911,465) for disclosure threshold calculations under FSA rules.
- Review the price range paid (1,175.0 to 1,198.0 pence) against market prices on February 18, 2011.